This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
To create a specialty pharmaco with greater R&D capabilities and a larger European sales force, privately held therapeutic development companies Strakan Group Ltd. (bone and skin disease) and ProSkelia SAS (musculoskeletal and hormone disorders) will merge in a stock swap. Each company will hold an equal share in the new entity, which is expected to file for an IPO within a year. Warburg Pincus, which owns over 37% of Strakan, and about 60% of ProSkelia, will have a 50% interest in the combined entity.
Payment Includes Stock
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?